H aemophilus infl uenzae causes illnesses ranging from local respiratory infection to serious invasive disease, including meningitis, epiglottitis, septic arthritis, and septicemia (1) . Among the encapsulated strains (a to f) that have been identifi ed, H. infl uenzae serotype b (Hib) is the most virulent (1) (2) (3) (4) . Nonencapsulated (nontypeable) strains are usually associated with noninvasive infections but can cause invasive disease, including neonatal sepsis (2) (3) (4) (5) . Historically, Hib was the leading cause of bacterial meningitis in the United States and Canada (6) . However, since the introduction of Hib capsular polysaccharide-protein conjugate vaccine in 1988, the incidence of invasive Hib disease has declined dramatically. Data from the Centers for Disease Control and Prevention (CDC) show invasive Hib disease in the United States has decreased by 99% to <1 case per 100,000 children <5 years of age (7) . Similar declines have been documented in Canada (8) .
Indigenous people, defi ned as the original people of Alaska (Alaska Native people) and northern Canada (aboriginal people), are at increased risk for Hib disease (8) (9) (10) (11) (12) than the general populations of the United States and Canada, and the risk for disease peaks at an earlier age (12) (13) (14) . While Hib vaccination led to the rapid decline of Hib disease in all populations including indigenous groups, indigenous children continue to have higher rates of Hib disease than nonindigenous children (12, 15) .
With widespread vaccination against Hib, concern has been raised about the potential for replacement disease caused by non-type b encapsulated strains. Protection conEpidemiology of Haemophilus infl uenzae Serotype a, North American Arctic, [2000] [2001] [2002] [2003] [2004] [2005] ferred by the Hib vaccine is specifi c to the type b polysaccharide capsule. It was suggested that reducing carriage of the vaccine type may open an ecologic niche, allowing increased colonization with non-type b strains of H. infl uenzae with the potential to become invasive (6, 16 ).
Non-type b H. infl uenzae disease is uncommon in children; however, since the introduction of Hib vaccine, the relative importance of infections due to nonencapsulated and non-type b encapsulated H. infl uenzae has increased (3). Infections caused by nonencapsulated strains are more common in adults and are more likely to be associated with pneumonia, whereas infections caused by encapsulated strains tend to occur in younger children with a predominance of meningitis and bacteremia (3, 17) . Non-type b H. infl uenzae appears to be more common in persons with underlying medical illnesses, such as immunosuppressive conditions (3, 4, 17) . The extent to which non-b H. infl uenzae causes invasive disease is not fully known (17) . In some countries, only Hib disease is reportable; therefore, information on other serotypes is lacking. However, numerous case reports of invasive H. infl uenzae disease caused by encapsulated non-b serotypes, particularly types a, e, and f, have been published (6, 10, 11, (18) (19) (20) .
Although uncommon, H. infl uenzae serotype a (Hia) has been reported to cause invasive disease, meningitis, pneumonia, and sepsis (3, 20) . Hia disease may occur more frequently in indigenous populations (10, 11, 21) . Reports of invasive H. infl uenzae disease have identifi ed Hia in 7.8% of Australian aboriginal children and 16.7% of Apache children with invasive disease (10, (21) (22) (23) . The Navajo and White Mountain Apache populations have a higher rate of Hia disease than the general US population, and Hia is now a leading cause of invasive H. infl uenzae disease in these populations (10) . Although high rates were discovered during the period of surveillance (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) , significant increases in incidence were not found (10) . Seasonal, temporal, and geographic clustering was not demonstrated. An outbreak of invasive Hia has recently been described in Alaska (11) , and data from the International Circumpolar Surveillance (ICS) Program suggest that the number of cases of Hia has increased in both Alaska and northern Canada. The objectives of this study were to characterize cases of invasive Hia, to examine incidence rates over time, and to assess the relatedness of Hia isolates by molecular typing.
Methods
ICS, a population-based surveillance system for invasive bacterial diseases established in 1999, includes laboratory-based surveillance for 
Laboratory Methods
Isolates were streaked onto chocolate agar to check for purity and confi rmed to be H. infl uenzae. Confi rmation tests included a requirement for both X (hemin) and V (nicotinamide adenine dinucleotide) growth factors (Oxoid, Hampshire, UK), Gram stain, and serotyping by slide agglutination.
Antimicrobial Susceptibility Testing
Susceptibility testing in Alaska was performed by using Etest (AB Biodisk, Solna, Sweden). A direct colony suspension equivalent to a 0.5 MacFarland standard was prepared in Mueller-Hinton broth from an overnight culture. Haemophilus Test Medium (Remel, Lexna, KS, USA) was added to produce a confl uent lawn of growth, and then Etest strips were placed onto the plate. The plates were then incubated for 20-24 hours at 35°C in 5% CO 2 . The MIC was read at the point of intersection of growth and the strip. Susceptibility of H. infl uenzae to the following antimicrobial drugs was tested: ampicillin, ceftriaxone, meropenem, chloramphenicol, and trimethoprim-sulfamethoxazole (TMPsulfa). Susceptibility data were not available from Canada.
Serotyping
Capsular serotyping was performed by slide agglutination with Difco antisera (Difco, Detroit, MI, USA) in Alaska and Remel antisera (Remel Europe Ltd, Dartford, UK) in northern Canadian laboratories (with the exception of the Laboratoire de Sante Publique in Quebec, which used PCR). If no capsular polysaccharide was present, the isolate was classifi ed as nontypeable by slide agglutination. Known positive and negative controls were run weekly, and each culture was screened in saline alone to check for autoagglutination. Since 2005, laboratories have participated in an ongoing H. infl uenzae quality control program.
Pulsed-fi eld Gel Electrophoresis (PFGE) and PCR
A selection of invasive isolates of Hia from cases in Alaska and northern Canada that tested positive for serotype a by both slide agglutination and genotype-specifi c PCR (24) were examined by PFGE with the use of the restriction enzymes SmaI and ApaI digestions (18, 25) at the CDC laboratory in Anchorage, Alaska. The fragments were resolved with a CHEF DRII (Bio-Rad, Hercules, CA, USA) (2.2-to 35-s switch times) at 175V for 21 hours. DNA banding patterns were analyzed with BioNumerics version 3.0 software (Applied Maths, Sint-Martens-Latem, Belgium). Percentage similarities were identifi ed on a dendrogram derived from the unweighted pair group method by using Dice coeffi cients and a band position tolerance of 1.5%. A similarity coeffi cient of 80% (<3-band difference) was used to defi ne related groups. The IS1016-bexA deletion was amplifi ed from genomic DNA by PCR using sense IS1016 (5′-ATTAGCAAGTATGCTAGTCTAT-3′) and antisense bexA (5′-CAATGATTCGCGTAAATAATGT-3′) primers (26) .
Statistical Analysis
Data were double entered into Paradox v9.0 (Corel, Ottawa, Ontario, Canada), and analyzed by using Epi Info version 6.04b (CDC, Atlanta, GA, USA) and StatXact version 6.2 (CYTEL Software Corp., Cambridge, MA, USA). Statistical differences in rates between periods and between countries were assessed by using a 2-sample Poisson test; p values are exact when appropriate.
Results

Descriptive Epidemiology
We identifi ed 138 cases of invasive H. infl uenzae disease from 2000 through 2005; serotype data were available for 132 (96%) of the isolates. Among these, 44 (33%) were nontypeable (Alaska 27; northern Canada 17). Of the remaining 88 isolates, 42 (48%) were serotype a, 27 (31%) serotype b, 12 (14%) serotype f, 4 (5%) serotype d, 2 (2%) serotype c, and 1 (1%) serotype e (Figure 1) . The proportion of illnesses that resulted in death among Hia, encapsulated non-a, and nontypeable isolates was 5% (2/37), 14% (6/42), and 15% (6/40), respectively.
Among the 42 Hia isolates, 30 (71%) occurred in children <2 years of age; 4 (10%) occurred in children 2-5 years of age; the remaining 8 (19%) occurred in adults (range 21-73 years). Ethnicity data were available for 38 cases; 35 (92%) occurred in indigenous people. The median age among case-patients was 1.1 years (range 3 months to 73 years) and did not differ signifi cantly by country. Overall, 62% were male (Table 1) Alaska (11) . No clusters >2 cases in 1 village over a period of 2 months were observed in northern Canada. No pattern of increasing incidence rates was seen over the study period.
Incidence Rates by Age
Overall crude annualized incidence of invasive Hia for the 6-year study period was 0.9 cases per 100,000 population. In Alaska and northern Canada, crude annualized incidence rates were 0.3 and 3.9 cases per 100,000 population, respectively. Annualized incidence rates of invasive Hia in children <2 years of age were 19.7 cases per 100,000 population; annualized rates in Alaskan and northern Canadian children <2 years were 5.7 and 79.1 cases per 100,000 population, respectively (p<0.001, Table 2 ).
Incidence Rates by Ethnicity
The overall annualized crude incidence rates of invasive Hia over the study period in indigenous and nonindigenous people were 2.9 and 0.2 cases per 100,000 population, respectively. Among indigenous people, the overall annual crude incidence rates ranged from 2.0 to 4.0 cases per 100,000 population during the study period; annualized indigenous incidence rates in Alaska and northern Canada were 1.1 and 5.9 cases per 100,000 population, respectively (Table 2) . Among indigenous children <2 years of age, the overall annualized incidence rate was 52.6 cases per 100,000 population, 20.9 and 101.9 cases per 100,000 persons in Alaska and northern Canada, respectively (Table 2) .
Clinical Illness
Among all ages, the most common clinical syndromes were meningitis (33%) and pneumonia (29%), followed by septic arthritis (12%). Clinical manifestations differed between children and adults. As noted previously, all pediatric cases occurred in children <5 years of age. Adult case-patients were 21-73 years of age. Children were more likely to exhibit meningitis, and adults were more likely to exhibit pneumonia; septic arthritis was reported among 5 (15%) pediatric patients. Clinical features were similar in Alaska and northern Canada. No cases of epiglottitis were reported (Table 3) .
Of the 37 case-patients with known hospitalization status, 35 (95%) were hospitalized with a median duration of 8 days. Case-patients in Alaska had a shorter median duration of hospitalization than those in northern Canada (6.5 vs. 9.0 days). Outcome information was available for 37 cases. Two patients (1 indigenous child, 1 nonindigenous adult) with invasive Hia died ( Table 1) . Both patients who died were diagnosed with pneumonia; neither had a history of immunodefi ciency noted in the chart.
Recurrence
Two Alaskan Hia patients had recurrent disease. In 1 patient, the clinical manifestation was septic arthritis in both occurrences (4 months before recurrence). In the second patient, the initial clinical syndrome was pneumonia, followed by meningitis 4 months later. Both of these patients were <1 year of age when fi rst brought for treatment. Neither child had documented immunodefi ciency (11) . No recurring cases of Hia were documented in northern Canada.
Antimicrobial Susceptibility Testing
All 11 Hia isolates from Alaska were susceptible to ampicillin, ceftriaxone, meropenem, and chloramphenicol. Ten of 11 Hia isolates from Alaska were tested for TMP- 
PFGE and PCR analysis
PFGE was performed on 9 Hia isolates from Alaska and 19 isolates from northern Canada. With 1 exception, all isolates were found to be closely related (<3-band difference) with a Dice correlation of >85% ( Figure 2 ). All 28 isolates were negative for the IS1016-bexA deletion by PCR.
Discussion
Our data demonstrate that 69% of invasive H. infl uenzae disease in the North American Arctic is now caused by non-b serotypes (Alaska 51%; northern Canada 89%) with serotype a comprising almost half of cases (Alaska 24%; northern Canada 74%). Hia is now the most prevalent serotype in the North American Arctic. The clinical features of invasive Hia cases were similar to those of invasive disease caused by Hib. The overall annualized incidence of Hia in children <2 years of age living in the North American Arctic was 19.7 cases per 100,000 children (Alaska 5.7; northern Canada 79.1) in contrast to the rate of 0.83 cases of non-type b invasive H. infl uenzae disease among US children <5 years of age (7). The overall annualized incidence rate among indigenous children <2 years of age residing in the North American Arctic was particularly high at 52.6 cases per 100,000 children (Alaska 20.9; northern Canada 101.9).
Widespread use of Hib conjugate vaccine has resulted in a dramatic decline in invasive Hib disease in the United States and Canada (7, 8) , including among indigenous children in the North American Arctic (7, 8, 14) and the southwestern United States (12, 27) . However, the potential for serotype replacement remains a concern (16). Three population-based studies have documented small increases in the incidence of non-type b H. infl uenzae disease after the introduction of the Hib conjugate vaccine (28) (29) (30) . Several recent studies conducted in different countries have demonstrated a predominance of serotype a disease. A study by Tsang et al. in Manitoba, Canada, found that most of the 52 H. infl uenzae cases reported during 2000-2004 were caused by serotype a (50%) or nonserotypeable isolates (38.5%) (31). Ribeiro et al. noted an 8-fold increase in the incidence of Hia meningitis from the prevaccine (0.02 per 100,000 population) to postvaccine period (0.16 per 100,000 population) in Brazil (32) . However, more recently published data by this group demonstrate that the increase in incidence during the year following vaccine introduction was not observed in subsequent years (33) . A study by Millar et al. has demonstrated high rates of invasive Hia disease among Navajo and White Mountain Apache children in the southwestern United States, although no increase in Hia incidence was noted after the introduction of Hib vaccine (10) .
Clinical manifestations of invasive Hia disease were similar to those of invasive Hib disease in the prevaccine era (29) . Meningitis was more common among Hia infections than in infections caused by encapsulated non-a and non-typeable Hi infections (37% vs. 24% and 12%, respectively, p = 0.05); conversely, pneumonia was less common (32% Hia vs. 41% encapsulated non-a H. infl uenzae and 40% nontypeable H. infl uenzae); however, this fi nding was
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Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 1, January 2008 (34) . There are several possible explanations for the high proportion of Hia among invasive H. infl uenzae disease in the surveillance population. First, an increase in virulence might explain the current predominance of serotype a. The IS1016-bexA deletion enables production of more capsule, which is thought to be the major virulence factor for invasive disease (26, 35) . However, Hia isolates from Alaska or northern Canada tested negative for the bexA deletion, and it appears unlikely that the high rates of invasive Hia disease, particularly among indigenous children in this region, are due to introduction of a particularly virulent strain of Hia. If a new highly virulent Hia strain were introduced into the North American Arctic in the postvaccine period, subtyping data may show a clonally restricted pattern. We found a high degree of relatedness with a predominance of 1 clone across the North American Arctic. However, these data do not directly support the introduction of a virulent clone because other studies suggest limited genetic diversity of Hia (18, 36) . Second, widespread use of Hib conjugate vaccine and the subsequent reduction in Hib colonization may have opened an ecologic niche for increased colonization with Hia or other non-Hib strains. Little data regarding carriage of non-type b strains of H. infl uenzae are available; however, an investigation of a cluster of 5 of the invasive Hia cases in Alaska found that among 31 close contacts of casepatients, 5 (16%) were colonized with Hia. Two of the 3 case-patients were infants with recurrent Hia disease; reexposure is the likely explanation for disease recurrence (11) . Finally, a preexisting background rate of non-b serotype disease may have simply been uncovered due to the decreasing Hib rates. Further studies of invasive H. infl uenzae disease are needed to describe clinical and epidemiologic features, characterize the pattern and rates of colonization, determine risk factors for carriage, and further characterize the strains by using molecular techniques.
Hia disease raises many questions from a public health response perspective. While chemoprophylactic regimens are well described for contacts of persons with Hib disease (37) , the utility of chemoprophylaxis or other public health prevention measures for non-b typeable disease such as Hia is not clear. Further research is needed to provide clear guidance to practicing physicians caring for patients with Hia disease.
This study has several limitations. Alaskan and northern Canadian data on non-b invasive H. infl uenzae disease were not collected in the pre-Hib conjugate vaccine era, making it diffi cult to determine baseline or prevaccine incidence of serotype a in this region. We did not collect detailed clinical and demographic information beyond what was available from medical record review, and therefore we were not able to assess other factors (e.g., H. infl uenzae carriage among case-patients, within the community, or among close contacts). In addition, most H. infl uenzae isolates are serotyped by using slide agglutination only. Because PCR is not yet routinely used throughout the ICS network for serotyping, nontypeable strains could have been misclassifi ed as encapsulated strains.
This article analyzed population-based surveillance for invasive H. infl uenzae disease across the North American Arctic. We identifi ed a high proportion of non-b serotypes over the 6-year study period, with particularly high rates of invasive disease caused by Hia. The reason for these high rates of invasive Hia disease is unknown and is likely multifactorial. While Hia incidence rates are high among particular groups in the North American Arctic, case numbers remain low (4-9 cases per year) and are lower than Hib rates in the prevaccine era. Hib vaccination remains one of the great public health success stories. Continued surveillance for H. infl uenzae disease is needed; however, to identify emerging problems and provide data necessary to develop effective prevention strategies. The changing epidemiology of invasive H. infl uenzaedisease highlights the importance of continued surveillance for invasive H. infl uenzae disease in regions of the world where Hib conjugate vaccine is currently in use. ICS will continue to monitor invasive disease caused by all H. infl uenzae serotypes in the North American Arctic and other participating Arctic countries.
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